Exosens enters into exclusive negotiations to acquire Noxant, specialized in high performance cooled infrared cameras
18 Novembre 2024 - 7:30AM
UK Regulatory
Exosens enters into exclusive negotiations to acquire Noxant,
specialized in high performance cooled infrared cameras
EXOSENS ENTERS INTO EXCLUSIVE
NEGOTIATIONS TO ACQUIRE NOXANT, SPECIALIZED IN HIGH PERFORMANCE
COOLED INFRARED CAMERAS
PRESS RELEASE
MÉRIGNAC – PALAISEAU, FRANCE – NOVEMBER, 18th
2024
- Exosens
announces it has entered into exclusive negotiations to acquire
Noxant, a specialist in high-performance cooled infrared
cameras.
-
This acquisition would enhance Exosens' technology platform
by adding advanced cooled infrared camera cores for OEM partners,
particularly in the Midwave Infrared (MWIR) range.
- This new
acquisition would mark another milestone in Exosens' growth
strategy, with significant synergies anticipated between Noxant and
its imaging business, including Telops (acquired in
2023).
Exosens (Euronext FR001400Q9V2 – EXENS), a
high-tech company dedicated to mission-critical amplification,
detection, and imaging technology, has entered into exclusive
negotiations with French-based Noxant, specialized in the
development of high-performance cooled infrared cameras. This
acquisition would enable Exosens to expand its product offerings
and to reinforce its position as a leading provider of advanced
imaging solutions for integrators. Noxant serves applications in
surveillance, scientific research and industrial testing, as well
as in gas detection, which would make it a strong synergistic
addition to Exosens’ infrared offering.
Expanding Infrared Capabilities with
Strategic Complementarity
“Through this acquisition, we would broaden
Exosens' technological spectrum by offering cutting-edge cooled
infrared solutions to meet the growing demands of our OEM
customers. Noxant's expertise in cooled infrared technology aligns
perfectly with our mission to deliver high-performance, reliable
imaging solutions for critical applications. Furthermore, the
synergies between Noxant and Telops would strengthen our R&D
capabilities and accelerate our innovation in infrared
technologies.” stated Jérôme Cerisier, CEO of
Exosens.
Noxant’s range of high-performance MWIR cooled
camera cores provides complementary capabilities that meet the
increasing demand for advanced infrared solutions in drone-based,
industrial control and other applications where camera integration
is required. Primarily serving OEMs, Noxant brings commercial
complementarity with Telops, targeting more end users. This
difference would create opportunities for sales synergies through
cross-selling of Exosens' expanded customer base.
Commitment to High-Performance
Imaging
“Joining forces with Exosens, a company that
shares our commitment to excellence in high-performance imaging,
would be a perfect match enabling us to continue delivering
advanced cooled infrared technology to our customers while
benefiting from Exosens' vast resources and expertise and a larger
GoToMarket.” commented Laurent Dague, Chairman of
Noxant.
Noxant has generated revenue of approximately
EUR 12 million for the financial year ended 30 June 2024 and has 22
employees1. The transaction is expected to be finalized
in the coming months, subject to completion of the consultation of
the employees’ representative body of Noxant and customary
clearances and approvals.
This acquisition pursues Exosens' growth
strategy, and would come in addition to the three transactions
announced since its IPO last June, namely Centronic (United
Kingdom), LR Tech (Canada) and NVLS (Spain). The four companies
generated a combined total revenue of €38 million in their last
reported fiscal year (in local GAAP accounting standards).
ABOUT
EXOSENS:
Exosens is a high‐tech company, with more than 85 years of
experience in the innovation, development, manufacturing and sale
of high‐end electro‐optical technologies in the field of
amplification, detection and imaging. Today, it offers its
customers detection components and solutions such as travelling
wave tubes, advanced cameras, neutron & gamma detectors,
instrument detectors and light intensifier tubes. This allows
Exosens to respond to complex issues in extremely demanding
environments by offering tailor‐made solutions to its customers.
Thanks to its sustained investments, Exosens is internationally
recognized as a major innovator in optoelectronics, with production
and R&D carried out on 11 sites, in Europe and North America
and with over 1,700 employees. Exosens is listed on
compartment A of the regulated market of Euronext Paris ﴾Ticker:
EXENS – ISIN: FR001400Q9V2﴿. Exosens is included in the CAC
Small, CAC Mid & Small and CAC All-Tradable indices, and is a
member of Euronext Tech Leaders segment.
For more information: exosens.com
Forward-looking
statements
Certain information included in this press release are not
historical facts but are forward-looking statements. These
forward-looking statements are based on current beliefs,
expectations and assumptions, including, without limitation,
assumptions regarding present and future business strategies and
the environment in which Exosens operates, and involve known and
unknown risks, uncertainties and other factors, which may cause
actual results, performance or achievements to be materially
different from the forward-looking statements included in this
press release. These risks include those described in chapter 3 of
Exosens’ registration document approved by the French Autorité
des marchés financiers under number I.24-0010 on 22 May
2024.
Media contacts for
Exosens:
Brunswick group – exosens@brunswickgroup.com
Laetitia Quignon, + 33 6 83 17 89 13
Nicolas Buffenoir, + 33 6 31 89 36 78
1 Audited figures established under local French GAAP.
- EXOSENS - NOXANT - Press release - VDEF - EN
Grafico Azioni Exosens (EU:EXENS)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Exosens (EU:EXENS)
Storico
Da Nov 2023 a Nov 2024
